- In patients with severe hemophilia A, standard treatment is regular prophylactic and episodic intravenous infusions of factor VIII. However, these treatments are burdensome, especially for children, and may lead to the formation of anti–factor VIII alloantibodies (factor VIII inhibitors). Emicizumab (ACE910), a humanized bispecific antibody mimicking the cofactor function of factor VIII, was developed to abate these problem
- CONCLUSIONS Once-weekly subcutaneous administration of emicizumab markedly decreased the bleeding rate in patients who had hemophilia A with or without factor VIII inhibitors. (Funded by Chugai Pharmaceutical; JapicCTI number, 121934.)
- N Engl J Med 2016;374:2044-53. DOI: 10.1056/NEJMoa1511769 Factor VIII–Mimetic Function of Humanized Bispecific Antibody in Hemophilia A Midori Shima, M.D., Ph.D., Hideji Hanabusa, M.D., Ph.D
Dr. Jayaprakash
Superintendent, ICH.
Institute of Child Health.
Gov. Medical College Kottayam.
Kerala, India.